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Introduction: By convention, a contralateral breast cancer (CBC) is treated as a new primary tumor, independent of
the first cancer (BC1). Although there have been indications that the second tumor (BC2) sometimes may represent
a metastatic spread of BC1, this has never been conclusively shown. We sought to apply next-generation
sequencing to determine a “genetic barcode” for each tumor and reveal the clonal relationship of CBCs.
Methods: Ten CBC patients with detailed clinical information and available fresh frozen tumor tissue were studied.
Using low-coverage whole genome DNA-sequencing data for each tumor, chromosomal rearrangements were
enumerated and copy number profiles were generated. Comparisons between tumors provided an estimate of
clonal relatedness for tumor pairs within individual patients.
Results: Between 15–256 rearrangements were detected in each tumor (median 87). For one patient, 76 % (68 out
of 90) of the rearrangements were shared between BC1 and BC2, highly consistent with what has been seen for
true primary-metastasis pairs (>50 %) and thus confirming a common clonal origin of the two tumors. For most of
the remaining cases, BC1 and BC2 had similarly low overlap as unmatched randomized pairs of tumors from
different individuals, suggesting the CBC to represent a new independent primary tumor.
Conclusion: Using rearrangement fingerprinting, we show for the first time with certainty that a contralateral BC2
can represent a metastatic spread of BC1. Given the poor prognosis of a generalized disease compared to a new
primary tumor, these women need to be identified at diagnosis of CBC for appropriate determination of treatment.
Our approach generates a promising new method to assess clonal relationship between tumors. Additional studies
are required to confirm the frequency of CBCs representing metastatic events.* Correspondence: Sara.Alkner@med.lu.se; Sofia.Gruvberger@med.lu.se
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Contralateral breast cancer (CBC) is today treated as a
new primary tumor, independent of the first breast can-
cer (BC1). However, whether the second tumor (second
breast cancer (BC2)) always is a new independent pri-
mary breast cancer, or in some cases could represent a
metastatic spread from BC1, remains unclear. Support-
ing this possibility are recent studies showing the lymph
node status of BC1 to influence risk of CBC and the
time interval between BC1 and BC2 to affect prognosis
after CBC [1–4]. If some CBCs are in fact metastatic
events, today’s clinical standard of diagnostic work-up
and the treatment of patients with CBC as metastasis
would need to be revised.
Various characteristics such as X-chromosome inactiva-
tion status, p53 mutations, partial allelotyping, microsatel-
lite instability, and comparative genomic hybridization
(CGH) analysis have been used to compare BC1 and BC2
in CBC patients [5–12]. These previous studies suggest
that the majority of CBCs appear clonally independent
from BC1, although some have features similar enough to
the primary tumor that they could potentially represent a
metastatic spread [6, 8–10, 13]. However, prior studies
utilized methods and techniques that are limited in
resolution and were generally not specific enough to dem-
onstrate an unequivocal clonal relationship between BC1
and BC2. For example, while a differing X-chromosome
inactivation status indicates two distinct progenitor cells, a
similar status must be considered noninformative [13].
Finding the same p53 mutation in two tumors could indi-
cate a similar origin [6]. However the p53 gene has muta-
tional hotspots, germline mutations are possible, and
certain subtypes, such as basal-like tumors, have a greatly
elevated p53 mutation rate [14], presenting a risk for mis-
classifications. Consequently, neither X-chromosome in-
activation status nor p53 mutation analysis can with
certainty confirm a clonal relationship [5, 6, 12].
Using array CGH, bilateral cancers have been shown
to share genomic imbalances [9, 10]. This could indicate
a clonal relationship, but another possibility is that their
development in a common milieu and genetic background
could lead to pathogenetically similar tumors that are in
fact independent cancers. Indeed, a high similarity of
allelic imbalances has been seen in simultaneously
developing breast cancers in monozygotic twins, and
allelotypes of CBCs developing synchronously were
found to be more alike than metachronous CBCs
[7, 15]. Furthermore, the gene expression-based in-
trinsic subtypes of breast cancer can largely be reca-
pitulated using DNA copy number variation (CNV)
profiles [16], presenting a risk that nonclonal tumors
or even those from different patients but of the
same intrinsic subtype could appear similar by CNV
profiles.Recent studies have shown that breast cancer genomes
are highly disorganized and can harbor tens to hundreds
of chromosomal rearrangements [17, 18]. Interestingly,
chromosomal rearrangements in breast cancer appear to
be highly specific, and thus the set of rearrangements in
any given tumor can serve as unique “fingerprint” or
“barcode” of that tumor. This is in contrast to somatic
point mutations, for which there are recurrent mutations
across several genes that may be shared between tumors
in unrelated persons. Importantly, it has been shown
that extensive clonal diversity exists for point mutations
within the same breast tumor mass, in contrast to struc-
tural chromosomal changes [19]. Therefore, chromo-
somal rearrangements are ideal for studies of clonal
origin.
Until recently, however, a lack of feasible and compre-
hensive methods to study chromosomal rearrangements
has prevented this chromosomal approach from being
fully utilized. With the recent advancement of next-
generation sequencing, global characterization of chromo-
somal rearrangements is now possible. Herein we have
characterized the genomes of contralateral breast tumors
using whole genome sequencing (WGS) to enumerate
chromosomal breakpoints, serving as unique tumor bar-
codes, to determine clonal relationships between CBCs.
For the first time we show with certainty that CBC can
represent a metastatic spread of the first tumor. Given the
poor prognosis of a generalized disease compared with a
new primary tumor, these women need to be identified at
diagnosis of CBC for appropriate determination of treat-
ment and diagnostic work-up. We hereby present a prom-
ising method for determining the clonal relationship




Fresh frozen tumor tissue from 10 CBC patients with
detailed patient and tumor information [1] and normal
blood DNA from three of these patients and seven unre-
lated persons were obtained from the South Sweden
Breast Cancer Group’s tumor bank. Nine patients had
two invasive tumors, and in Patient 1 BC2 was an in-situ
lesion. This patient was included to exemplify a case
presumed to be two independent primary tumors. The
samples’ quality and percentage of tumor cells were con-
trolled with tissue arrays, evaluating an adjacent tissue
piece. Paraffin material was available for 13 of 20 tu-
mors, allowing histopathological reevaluation by a path-
ologist (AE). For the remaining cases these data were
abstracted from the patient’s chart. The project includes
all necessary patients’ consent regarding participation
and right to publish, and was approved by the Regional
Ethical Review Board of Lund (LU240-01). All data were
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Whole genome sequencing and data analysis
Using DNA extracted from frozen tumor samples and
normal blood samples, whole-genome paired-end
Illumina (San Diego, CA, USA) sequencing libraries
were generated, sequenced, and aligned to the human
reference genome (see Additional file 1).
Sequencing data were analyzed bioinformatically to
identify chromosomal rearrangements in each tumor
and normal DNA sample (see Additional file 1). Initial
filtering removed centromeric, segmentally duplicated re-
gions, and intrachromosomal rearrangements <7 kb.
Germline rearrangements (both ends matching within ±1
kb in any normal sample) were removed. For every com-
parison between two tumors (whether from the same pa-
tient or between patients), each rearrangement was
classified as either shared or specific to one tumor as fol-
lows: rearrangements were considered shared between
two tumors if the genomic coordinates for both ends of
the rearrangement matched within ±500 base pairs; or to
compensate for potential tumor subclonality (in case a re-
arrangement was present only in a subclone and therefore
represented by fewer reads), each remaining rearrange-
ment in a tumor was computationally “looked-up” in the
aligned sequence BAM file of the other tumor, and if ≥1
read pairs matched within ±1 kb on both ends then the re-
arrangement was classified as shared. In addition, all rear-
rangements looked up and supported by at least one read
pair in the normal samples were removed. The combined
shared rearrangement fraction was calculated as the num-
ber of shared rearrangements divided by the number in
the union of all rearrangements found in the compared
tumors.
CNV was evaluated from the WGS data. CNV profiles
were compared between samples based on windows
delineated by the union of their segmentation breaks
taking into account both copy number “state” (gain,
normal, or loss) and “slope”, corresponding to the differ-
ence between the current and previous window’s state
(see Additional file 1). Windows with the same state and
slope were considered shared. The fraction of shared ab-
normal CNV events between two tumors was calculated
after excluding windows with a normal diploid state in
both tumors.
The rearrangements of each tumor were plotted using
Circos [20], and rearrangement and CNV profiles were
drawn using standard R graphical libraries [21]. Detailed
methods are available in Additional file 1.
PCR validation of rearrangements
Rearrangements were validated with conventional PCR.
Using our in-house SplitSeq bioinformatics pipeline, thelocal sequence around each breakpoint was retrieved
[22]. Rearrangements for validation were randomly
selected from all enumerated rearrangements of four
patients (Patients 2, 6, 8, and 9). Primers were
designed and touchdown PCR was performed on
DNA extracted from the BC1 and BC2 (further
details in Additional file 1). As germline control,
matched normal DNA was used where available
(Patient 9) or a normal DNA pool was created from




Tumor and treatment characteristics are presented in
Table 1. Patient 10 was a known BRCA1 mutation car-
rier. Patient 3 had a local recurrence from BC2 7
months after diagnosis of CBC, treated with surgery and
endocrine therapy. Patient 1 had a local recurrence after
BC1 12 months before diagnosis of BC2, treated with
surgery, radiotherapy, and endocrine therapy. None of
the other patients had any local/regional recurrences.
Patient 4 developed mucosa-associated lymphoid tissue
lymphoma 61 months after BC2. To avoid the risk of
misdiagnosing metastases past this date, the diagnosis
date of the lymphoma was considered the last follow-up
date. For Patients 1 and 7, BC2 was diagnosed during
endocrine therapy.
Paraffin material was available for both tumors in
Patients 3, 4, 5, 6, 7, and 8 and for BC1 in Patient 2.
Here histopathological markers have been reevaluated
with immunohistochemistry by a pathologist. The cutoff
value for estrogen receptor (ER)/progesterone receptor
(PR)-positivity was >10 % positive cells. For the
remaining tumors these data are from the patient’s chart.
For most of these patients (Patients 1, 9, and 10) ER and
PR were measured with immunohistochemistry. For
Patient 2 BC1 ER and PR were measured in cytosol
(ER 140 fmol/mg protein, PR 170 fmol/mg protein; cut-
off value for ER/PR-positivity = 25 fmol/mg protein).
Chromosomal rearrangements
WGS was performed on the 10 CBC pairs employing a
strategy that combined low sequence coverage paired-end
sequencing with larger fragment sizes for improved phys-
ical genome coverage. The median sequence coverage was
6.5 (range 1.8–11.2) and the median physical coverage
was 14.7 (range 6.9–28.4) (Additional files 1 and 2). The
total number of rearrangements detected in each tumor
varied widely, from 15 to 256 with a median of 87 per
tumor (Fig. 1a, Table 2; all plots in Additional file 3).
We were first interested in ascertaining how often two
unrelated tumors from different individuals display iden-
tical chromosomal rearrangements because this would
Table 1 Clinical characteristics






ER PR HER2b Ki67 NHG Treatment Time interval
BC1 – BC2 (months)
Metastasis after BC2c
(months, location)
1 BC1 Left 61 Lobular No 32 No (0/4) Pos Pos UK UK 2 Tam 61 Yes (15, lung, liver, skeleton)
BC2 Right DCIS Yes 14 No (0/3) NA NA NA NA 3 None
2 BC1 Left 41 Ductal No 15 No (0/10) Pos Pos UK UK 2 None 5 No (249)
BC2 Right Ductal No 14 No (0/5) Pos Pos 2+ 9 % 3 None
3 BC1 Left 83 Ductal No 17 No (0/11) Neg Neg Neg 30 % 3 None 23 No (8)
BC2 Right Ductal No 25 No (0/12) Neg Neg Neg 75 % 3 None
4 BC1 Left 51 Ductal No 25 Yes (9/21, PG) Neg Pos 3+ 14 % 3 RT, CT (7 CMF) 24 No (61)
BC2 Right Ductal No 25 Yes (7/28, PG) Pos Pos Neg 16 % 3 RT, Tam
5 BC1 Left 43 Ductal No 10 No (0/23) Neg Neg Neg 80 % 3 RT, CT (9 CMF) 22 Yes (13, liver)
BC2 Right Ductal No 20 No (0/20) Neg Neg Neg 27 % 3 RT
6 BC1 Right 51 Lobular Yes 70 Yes (3/8, PG) Pos Pos Neg 28 % 2 RT, CT (9 CMF) 17 Yes (5, brain)
BC2 Left Lobular Yes 12 Yes (23/26, PG) Pos Neg Neg 22 % 2 CT (3 Doxo–2 T)
7 BC1 Right 52 Ductal No 16 No (0/11) Pos Pos Neg 21 % 3 RT, Tam 30 No (66)
BC2 Left Ductal No 16 No (0/1) Neg Neg Neg 40 % 3 CT (6 FEC)
8 BC1 Left 46 Lobular No 80 Yes (33/34, PG) Pos Pos Neg 4 % 3 RT, CT (9 FEC) 11 Yes (16, lung)
BC2 Right Lobular Yes 55 Yes (11/25, PG) Pos Pos Neg 5 % 2 RT, Tam + oophorectomy
9d BC1 Right 63 Ductal No 28 Yes (2/13) Pos Pos Neg UK 2 Tam–AI 0 Yes (62, skeleton)
BC2 Left Ductal No 55 Yes (1/12) Pos Pos Neg UK 3 RT, Tam–AI
10 BC1 Right 32 Ductal No 23 No (0/1) Neg Neg UK UK 3 RT, CT (6 FEC) 35 Yes (13, skin)
BC2 Left Ductal No 45 Yes (12/12) Neg Neg Neg UK 2 RT
AI aromatase inhibitor, BC1 first breast cancer, BC2 second breast cancer, CMF cyclophosphamide, methotrexate and fluorouracil, CT chemotherapy (cycles and regime used in parentheses), DCIS ductal carcinoma in
situ, Doxo doxorubicin, ER estrogen receptor, FEC fluorouracil, epirubicin, and cyclophosphamide, HER2 human epidermal growth factor receptor 2, NA not applicable, Neg negative, NHG Nottingham histological grade,
PG periglandular growth, Pos positive, PR progesterone receptor, RT radiotherapy, T docetaxel, Tam tamoxifen, UK unknown
aNumber of positive lymph nodes/number of investigated nodes in parentheses
bHER2 determined with immunohistochemistry (Herceptest) where score 0–1 has been classified as negative. For score 2+ and 3+ the individual score is given in the table
cIf the patient developed metastases, the time interval between BC2 and diagnosis of metastasis (months) and the site of the first metastasis is given within parentheses. In patients who do not develop metastases,
the follow-up period (months) is given within parentheses








































































































Fig. 1 a Chromosomal rearrangements for three patients visualized in Circos plots. b Copy number profiles for three patients. Orange denotes
events (rearrangements or copy number traces) specific to BC1, blue denotes events specific to BC2, and black denotes events shared between
BC1 and BC2. P3 Patient 3, P4 Patient 4, P8 Patient 8
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to incomplete filtering of germline events. For this, all
possible pairings of tumors between patients (excluding
the true within-patient pairing) were exhaustively com-
pared. This comparison showed that 0–25 rearrange-
ments (median 4) matched between any two random
tumors with a combined shared fraction (i.e., the frac-
tion of rearrangements shared between BC1 and BC2 di-
vided by the union of all rearrangements detected in
both tumors) ranging from 0 to 18 % (median 2 %;
Table 2). For the comparisons of matched patient CBCs,
on the other hand, the number of shared rearrange-
ments between BC1 and BC2 ranged between 6 and 68
(median 28) and the combined shared fraction varied be-
tween 6 and 76 % (median 13 %).
Patient 8 was a clear outlier and had the most similar
CBCs, with 76 % shared rearrangements between the
two tumors (68 shared rearrangements), 19 rearrange-
ments unique to BC1, and three rearrangements unique
to BC2 (Fig. 1a, Table 2). Patient 8’s extreme degree of
similarity of chromosomal rearrangements unequivocally
supports BC2 being the result of a metastatic spread
from BC1. Furthermore, in a separate study of matched
primary and distant metastases using the same experi-
mental approach, we have found that the average pri-
mary breast cancer shares well over one-half of its
chromosomal rearrangements with the distant metasta-
sis it seeds (results not shown; Tang and Gruvberger-
Saal, manuscript under review). Therefore, the 76 %
shared rearrangements between CBCs in Patient 8 is
highly consistent with known primary-metastasis pairs.Seven of the remaining CBC patients had much fewer
shared rearrangements between BC1 and BC2 with com-
bined shared fractions between 6 and 15 % (median 10 %),
most consistent with these CBCs having developed as inde-
pendent primary tumors (Fig. 1a, Table 2; Additional file 3).
However, Patients 2 and 6 had a rearrangement overlap
(39 % and 46 %) between that seen for unmatched
randomized tumor pairs and true tumor-metastasis
pairs (including Patient 8). The cases of Patients 2 and
6 are highly suspicious for contralateral metastasis, but
to classify them with certainty normal DNA samples
would be needed to rule out any remaining germline
rearrangements. Interestingly, for Patient 1, where BC2
was an in-situ lesion and included in the study as a
CBC pair presumably representing two independent le-
sions, 15 % of rearrangements matched between the tu-
mors. This overlap was considerably lower than the
overlap for Patient 8 (76 %) but well within the range
between CBC pairs when excluding the three most
similar patients (Patients 2, 6, and 8) (6–13 %).
The similarities and differences in chromosomal rear-
rangements between tumors are well illustrated in a
barcode plot, where all nonredundant identified rear-
rangements are arranged and their presence in each
tumor is denoted by a line (Fig. 2). For example, the
two tumors from Patient 3 were highly eventful yet
displayed distinct rearrangement barcodes spread
across the whole genome (Figs 1a and 2). Many tumors
exhibited localized areas of high density of rearrangements
suggestive of one catastrophic shattering event (chromo-
thripsis). Chromothripsis is thought to contribute to













1 BC1 7 15 47 15 18
BC2 7 40 18
2 BC1 53 64 83 39 15
BC2 53 124 43
3 BC1 28 151 19 9 10
BC2 28 203 14
4 BC1 17 256 7 6 18
BC2 17 75 23
5 BC1 27 67 40 13 20
BC2 27 170 16
6 BC1 62 86 72 46 23
BC2 62 111 56
7 BC1 33 128 26 12 22
BC2 33 173 19
8 BC1 68 87 78 76 28
BC2 68 71 96
9 BC1 20 84 24 10 25
BC2 20 128 16
10 BC1 6 58 10 7 28
BC2 6 30 20
Summary
Paired tumors Median 28 87 24 13 21
Minimum 6 15 7 6 10
Maximum 68 256 96 76 28
Random pairs Median 4 75 4 2 13
Minimum 0 6 0 0 6
Maximum 25 254 43 18 22
BC1 first breast cancer, BC2 second breast cancer
Summarized numbers for randomized matching
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consequence is an important driving force for early cancer
development and would probably be shared between clonal
tumors. For Patient 8 this appears to be true; the two
tumors share identical chromothripsis-like rearrangement
patterns in two localized hotspots on chromosomes 10 and
11 (Figs 1a and 2). On chromosome 11 alone the two tu-
mors share 38 identical intrachromosomal rearrangements,
while only five are specific to BC1 and none to BC2. Patient
4, on the other hand, has localized areas on 1q, 6p, and
chromosomes 17 and 18 of chromothripsis-like patterns
that only appear in BC1, whereas BC2 has specific high-
density areas on 6q. Patient 9, with a combined percentage
of shared rearrangements of 10 %, has very distinct heavily
rearranged areas on 11q and chromosome 12 unique to
BC1, while BC2 has areas suggesting chromothripsis onchromosomes 1, 3, and 11p that are not being shared with
BC1, further indicative of their nonclonal origin.
A number of cancer-associated genes (e.g., RB1,
RARA, CDKN2A, and PTEN) were found to be involved
in the enumerated rearrangements [23], probably con-
tributing to tumorigenesis (Additional file 4).
Indicative of a suitable reliability of our analysis pipeline,
68 rearrangements out of 86 (79 %) were confirmed by
PCR across the breakpoint junction as either specific to
BC1, specific to BC2, or shared. However, nine of these re-
arrangements (13 %) were also identified in the matched
normal DNA, or if unavailable were identified in a pool
of 44 normal DNA samples. Therefore, although our
pipeline results in a good accuracy of calls based on
the sequencing data, owing to the fact that matched
normal DNA were unavailable for most patients and
Chromosome Color Coding




































Fig. 2 Tumor genetic barcodes of chromosomal rearrangements for individual tumors. All nonredundant chromosomal rearrangements were
included and their presence in each tumor denoted by a line. The rearrangements were plotted in the order of genomic location for the end of
the fusion that appears first in the genome. Color coding below indicates which two chromosomes where involved in each rearrangement. BC1
first breast cancer, BC2 second breast cancer
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to some extent the contribution of rearrangements that
are present in the germline.Copy number variation
CNV profiles were also evaluated using the WGS data
(Fig. 1b; Additional file 3). The fraction of shared ab-
normal copy number events between CBC pairs ranged
between 10 and 28 % (median 21 %; Table 2). When
exhaustively comparing all pairings of tumors from dif-
ferent patients, the fraction of shared aberrant copy
number events ranged between 6 and 22 % (median
13 %), which was only slightly lower than that seen for
the matching tumor pairs. Again, the CBCs from Pa-
tient 8 had the highest fraction of shared aberrations
(28 %) and the CNV profiles appeared similar (Fig. 1b;
Additional file 3). Patient 1, with BC2 representing an
in-situ lesion, shared 18 % of the aberrant copy number
events between the two tumors.Clonal relationship between contralateral tumors
The analysis of genomic clonal similarities between tu-
mors can be visualized in two dimensions (Fig. 3). When
looking at chromosomal rearrangements, the majority of
the CBC pairs (blue) cluster together just slightly off the
cloud of randomly-paired tumors (red) (Patients 2 and 6
showed a somewhat higher similarity as discussed
above). Patient 8, on the other hand, is clearly distantly
separated from the other CBC pairs (including Patient 1
with an in-situ BC2) and from the randomized pairings.
For the CNV events this separation is not evident and
no patient CNV profiles are more similar than some of
the tumor pairings from different individuals. Based on
the analysis of rearrangements, however, we can con-
clude that BC2 from Patient 8 in fact is highly clonally
related to BC1.
Discussion
By harnessing the power of WGS-detected tumor-
specific chromosomal rearrangement barcodes, we have













































Fig. 3 Fraction of shared abnormal copy number events between
BC1 and BC2 plotted against the fraction of shared chromosomal
rearrangements between BC1 and BC2. All comparisons between
tumors from the same patient are plotted in blue, while all possible
random pairings of tumors from different individuals are shown in
red. P Patient
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cancer can arise as a metastatic clone from a tumor in
the contralateral breast. Among the 10 CBC pairs in this
study, the Patient 8 CBC pair exhibited 76 % rearrange-
ment similarity between the left and right tumors. Our
analyses showed that chromosomal rearrangements
rarely recurred among randomly paired samples (median
shared fraction, 2 %; median shared number, four rear-
rangements; Table 2), and hence chromosomal rear-
rangements uniquely characterized the tumors. In a
separate study of primary-metastasis pairs using the
same experimental approach, we have found that the
average primary breast cancer appears to share about 50 %
or more of its chromosomal rearrangements with the
distant metastasis it seeds (Tang and Gruvberger-Saal,
manuscript under review). This is highly consistent with
the genetic chromosomal rearrangement fingerprint of
Patient 8, and thus we can confidently conclude a clonal
relationship between BC1 and BC2 for this patient.
However, two patients showed intermediate levels of
rearrangement similarity (39 and 46 %). This is higher
than that seen in unmatched randomized pairing, but on
the lower end of what we have seen for primary-
metastasis pairs (including Patient 8). A limitation in
our study is the unavailability of matching normal DNA
for every CBC patient. WGS analysis of matching nor-
mal DNA would have allowed for complete filtering of
all germline chromosomal-rearrangement events and
CNVs. Although the vast majority of germline eventshave been removed by our data filtering steps and by
comparison with unmatched normal DNA samples from
the Swedish population, matched normal DNA would
probably have clarified the clonal relationship in these
two uncertain cases. Nevertheless, the purpose of this
study was to show that contralateral metastasis does
exist and can be reliably detected with newer technolo-
gies. Owing to the extreme degree of similarity of
chromosomal rearrangements in Patient 8, there is no
doubt of the clonal relationship between BC1 and BC2
in this patient. Further studies are needed, however, to
determine the prevalence of “metastatic CBC”, optimal
diagnostic work-up and treatment. In addition, further
comparisons between known primary-metastasis pairs
versus unrelated tumor pairs are required to find the op-
timal cutoff value for the fraction of shared rearrange-
ments indicating clonality, and to make sure that all
CBCs actually representing metastatic events are cor-
rectly identified.
Clinically, CBC events are today considered to be two
separate tumors, and adjuvant treatment is recom-
mended on the basis of the clinicopathological charac-
teristics of BC1 and BC2 individually. However, since
metastatic breast cancer has worse prognosis than and a
different treatment regimen from that for localized
breast cancer, our finding gives a new important per-
spective on the clinical management for women diag-
nosed with CBC. A more careful diagnostic work-up is
necessary in order to determine an appropriate treat-
ment strategy, and we have developed a novel approach
to ascertain the metastasis status of a CBC that is afford-
able and can be performed in a clinically relevant time
frame. In addition, access to normal DNA would not be
a problem in the clinic, increasing sensitivity and specifi-
city of the analysis.
Whether a patient with a contralateral metastasis has
an equally poor prognosis as a patient with distant me-
tastases at other sites (lung, liver, brain, etc.) or whether
the outcome associated with a contralateral metastasis, if
treated correctly, could be more similar to that of a local
or regional recurrence are questions that deserve further
study. If a contralateral metastasis represents a cancer
still prone to thriving mainly in breast tissue, or possibly
a local lymphatic spread to the contralateral breast, we
may with the right treatment still be able to prevent fur-
ther spread and a fatal outcome. If, on the other hand, a
contralateral metastasis is already a sign of an incurable
metastatic disease, treatment may instead be focused on
quality of life rather than intense adjuvant therapy.
Among our 10 patients, six developed generalized dis-
ease within 5–62 months from BC2. Patient 8, in whom
our analysis determined BC2 to be a contralateral metas-
tasis, was diagnosed with lung metastases 16 months after
BC2. Since she was treated with radiotherapy, tamoxifen,
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given could have helped in delaying development of fur-
ther metastases. Our study is too small to draw any con-
clusions regarding prognosis after contralateral metastasis,
but it is an important question with significant clinical im-
plications, which needs to be further evaluated.
An important issue is how one may identify patients
with a high risk of BC2 representing a metastasis instead
of a new primary tumor. Are there clinical indications as
to when contralateral metastasis should be suspected and
further investigation with WGS is warranted? Patient 8
had a very large BC1 (80 mm), widespread lymph node
metastasis, and both tumors were lobular type and had
similar hormone receptor, HER2, and Ki67 expression.
Further studies will show whether these characteristics
could be indicators of a risk for contralateral metastasis.
Of note, the Nottingham histological grade of Patient 8
was classified as grade 3 in BC1 and grade 2 in BC2. This
is particularly interesting since, using the traditional cri-
teria summarized by Chaudary et al. [24], bilateral carcin-
omas are considered independent if: the subsequent
tumor has an in-situ component; or the lesions are of dis-
tinct histological subtypes; or the subsequent cancer has a
better degree of differentiation; or there is no evidence of
local, regional, or distant metastases from the ipsilateral
lesion. Clearly, these clinical criteria do not accurately de-
tect the contralateral metastasis in our material. Further-
more, for seven of the remaining eight invasive CBC pairs,
the CBCs shared the same histological subtype and did
not have a better degree of differentiation for BC2 (data
on in-situ component unknown) and would consequently
be classified as possible metastases. Routine pathological
markers do not therefore appear to adequately separate
new primaries from contralateral metastases.
Since CBC tumors arise and develop in the same gen-
etic and environmental background, and genetic predis-
positions such as a germline BRCA1 mutation (also
associated with basal-like tumors) are more common
[25], it is conceivable that bilateral tumors more often
will be of the same intrinsic subtype and may accumu-
late similar patterns of mutations and copy number ab-
errations, even when they arise as independent tumors.
Indeed, while CNV profiles carried some information on
genomic similarities in our data, none of the matched
pairs had significantly more similar CNV profiles than
some unrelated tumors. However, using the rearrange-
ment barcodes, even Patient 10, a germline BRCA1 mu-
tation carrier, shared very few rearrangements between
BC1 and BC2 and a different clonal origin could be de-
termined (Additional files 3 and 4).
Conclusion
By using next-generation sequencing and an analytical
strategy based on chromosomal rearrangements, we canfor the first time show strong evidence that some CBCs
indeed represent a metastatic spread of BC1. Our ap-
proach generated a unique tumor barcode that can as-
sess the clonal relationship between tumors. This is a
promising new method not only for management of
CBCs, but also in a variety of other cancer types where
the question of clonality and tumor heterogeneity raises
important clinical issues. Although our study had the
disadvantage of a lack of matched normal DNA for most
patients, this would not be a problem in the clinical set-
ting, allowing for complete filtration of germline defects
and increasing specificity and sensitivity of the method.
Further studies are needed in order to identify the opti-
mal cutoff level to with certainty not miss any CBCs ac-
tually representing a metastatic event.
CBCs are today treated as two individual tumors, but
if BC2 instead represents a metastatic disease state the
patient would have a worse prognosis and require a dif-
ferent treatment than a new primary breast cancer. With
intensified treatment for these patients there may be a
possibility to prevent further spread, and avoid develop-
ment of a generalized incurable breast cancer.
Additional files
Additional file 1: presents a detailed description of supplemental
methods. (DOCX 30 kb)
Additional file 2: is Table S1 presenting sequencing statistics.
(DOCX 14 kb)
Additional file 3: is Figure S1 showing chromosomal
rearrangements visualized using Circos and copy number profiles
for all 10 CBC patients. Orange denotes events (rearrangements or
copy number traces) specific to BC1, blue denotes events specific to BC2,
and black denotes events shared between BC1 and BC2. P Patient.
(PDF 1524 kb)
Additional file 4: is Table S2 presenting a list of genes affected by
rearrangements and found in the COSMIC Catalogue of somatic
mutations in cancer [26]. (XLS 116 kb)
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